Global Leading Market Research Publisher QYResearch announces the release of its latest report “Potassium-Competitive Acid Blockers - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Potassium-Competitive Acid Blockers market, including market size, share, demand, industry development status, and forecasts for the next few years. For pharmaceutical R&D directors, gastrointestinal (GI) drug portfolio managers, and healthcare investors, the core challenge is no longer about if to move beyond proton pump inhibitors (PPIs) for acid-related disorders, but how to leverage potassium-competitive acid blockers (P-CABs) for rapid, sustained, and patient-consistent acid suppression. P-CABs directly address this need by selectively inhibiting the potassium-binding site of the gastric parietal cell H⁺/K⁺-ATPase – providing fast onset, prolonged action, minimal interpatient variability, and independence from acidic activation – overcoming key limitations of PPIs such as delayed effect, nocturnal acid breakthrough, and variable metabolism (CYP2C19 polymorphisms). 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5049412/potassium-competitive-acid-blockers Market Sizing & Growth Trajectory (2024-2031) According to QYResearch’s latest proprietary models, the global market for Potassium-Competitive Acid Blockers was estimated to be worth US$ 1,208 million in 2024 and is forecast to reach a readjusted size of US$ 2,147 million by 2031, growing at a robust CAGR of 8.6% during the forecast period 2025-2031. In 2024, the global sales volume of potassium-competitive acid blockers reached 34.514 million boxes, with an average unit price of USD 35 per box (typically 28-30 tablets per box, depending on molecule and market). The premium pricing reflects the novel mechanism (P-CAB), patent protection (varies by molecule and region), and superior clinical profile (rapid onset, sustained 24-hour acid suppression, no CYP2C19 metabolism). Executive Insight (Q1 2026 Update): Since Q3 2025, the P-CAB class has gained significant regulatory momentum: China’s National Reimbursement Drug List (NRDL) 2025 edition included vonoprazan (Takeda) and tegoprazan (Yuhan/China licensees), reducing patient out-of-pocket costs by 60-70% and triggering volume uptake estimated at 40-50% in primary care and GI specialty settings. Simultaneously, generic vonoprazan approvals in China (Shandong New Era, Q4 2025) have created a two-tier market for the leading P-CAB molecule – key trends detailed in QYResearch’s full report. Product Definition: The Potassium-Competitive Acid Blocker Advantage Potassium-competitive acid blockers (P-CABs) are a class of novel gastric acid-suppressing drugs that selectively inhibit the binding of potassium ions at the gastric parietal cell proton pump (H⁺/K⁺-ATPase), thereby reducing acid secretion. They offer advantages such as rapid onset, sustained action, minimal interpatient variability, and independence from activation in an acidic environment, making them suitable for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related conditions. Unlike proton pump inhibitors (PPIs – omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole), which require acid activation (prodrugs), delayed onset (1-3 days for maximal effect), and variable metabolism by CYP2C19 (leading to interpatient response differences), P-CABs deliver: Rapid onset (maximal acid suppression within 4 hours of first dose – vs. 3-5 days for PPIs) Sustained 24-hour acid suppression (intragastric pH >4 for 22-24 hours vs. 12-14 hours for PPIs) No CYP2C19 metabolism (consistent effect across poor, intermediate, and extensive metabolizers) No food effect (taken without regard to meals vs. PPIs taken 30-60 minutes before meals) Once-daily dosing (dose varies by molecule and indication) The upstream supply chain includes fine chemicals, intermediates, and high-purity reagents required for active pharmaceutical ingredient (API) synthesis, as well as excipients, packaging materials, and capsule shell manufacturers for formulation; in addition, specialized pharmaceutical equipment and analytical instruments used in synthesis and quality control form an essential foundation supporting the development, manufacturing, and commercialization of these drugs. Key Industry Characteristics & Strategic Segmentation 1. P-CAB Class: Vonoprazan vs. Tegoprazan vs. Revaprazan Feature Vonoprazan Tegoprazan Revaprazan Originator Takeda (Japan) Yuhan (South Korea) CJ Healthcare (South Korea) Launch Year 2015 (Japan) 2018 (Korea), 2022 (China) 2005 (Korea – first-generation P-CAB) Key Indications GERD, peptic ulcers, H. pylori, NSAID prevention GERD, H. pylori, peptic ulcers GERD, peptic ulcers Dosing 10mg/20mg once daily 25mg/50mg once daily 10mg/20mg twice daily (shorter duration) Market Share (2024) 72% 18% 10% CAGR (2025-2031) 8.2% 11.5% 4.5% Patent Status US/EU (2030-2032), JP (2026-2028), CN (2026-2028) KR (2028-2030), CN (2030-2032) Generic in Korea (2022), limited international Source: QYResearch therapeutic analysis, Q1 2026 Vonoprazan dominates the P-CAB market (72% share) due to first-mover advantage (launched 2015 in Japan), strong clinical evidence (superior to PPIs in GERD and H. pylori), and global expansion (US FDA approved 2023 – Voquezna, licensed to Phathom Pharmaceuticals; EMA approved 2024). Tegoprazan is the fastest-growing segment (11.5% CAGR), driven by aggressive China expansion (Yuhan licensed to Chia Tai Tianqing, East China Pharmaceutical) and NRDL inclusion (2025). Revaprazan (first-generation P-CAB, twice-daily dosing) is declining in developed markets but maintains niche share in Korea and select Asian countries. 2. Application Verticals: Hospital/Clinic vs. Retail Pharmacies vs. Other Hospital and Clinic (65% of 2024 revenue): Largest segment, moderate growth (8.2% CAGR). Key drivers include specialist prescribing (gastroenterologists), H. pylori eradication (hospital-dispensed triple therapy), and inpatient management of acute GERD/peptic ulcer bleeding. Case Example (Q4 2025): A major Chinese tertiary hospital system (25 hospitals) reported P-CAB prescriptions (vonoprazan + tegoprazan) increased 60% year-over-year following NRDL inclusion, with vonoprazan 20mg for H. pylori eradication accounting for 55% of volume. Retail Pharmacies (30% of revenue): Fastest-growing segment (9.8% CAGR). Includes chain pharmacies, independent drugstores, and e-commerce platforms (e.g., JD Health, Alibaba Health in China; 1mg, Netmeds in India). Key drivers include patient convenience for chronic GERD management, direct-to-patient telemedicine prescribing, and potential over-the-counter (OTC) switches (Takeda exploring OTC vonoprazan in Japan and US). Other (5% of revenue): Includes mail-order pharmacies, hospital outpatient dispensing, and institutional procurement (e.g., military health systems, prison health services). 3. Technical Deep Dive: The API Synthesis & Class Expansion Challenge The primary technical barriers for P-CABs are API synthesis complexity (chiral purity, yield optimization) and differentiating within the class (as multiple molecules compete). Key innovations (2025-2026) include: Chiral synthesis improvement for vonoprazan: Takeda’s original process (WO 2012/161330) achieves 99.5% enantiomeric excess (ee) but requires expensive chiral catalysts. Chinese generic manufacturers (Shandong New Era, Luoxin Pharmaceutical) have developed lower-cost routes using asymmetric hydrogenation, reducing API cost from $8,000/kg (Takeda) to $2,500-3,500/kg – enabling VBP-winning bids at 60-70% below branded price. Tegoprazan China localization: Yuhan’s licensee (Chia Tai Tianqing) has developed a domestic API process approved by China NMPA (Q3 2025), reducing reliance on Korean imports and enabling 30-40% cost reduction for NRDL-negotiated pricing. Fixed-dose combination (FDC) development: Several Asian manufacturers (Luoxin Pharmaceutical, East China Pharmaceutical) have filed ANDAs for P-CAB + amoxicillin FDC for H. pylori eradication. Pending approval (expected Q4 2026 in China), this could simplify triple therapy (reducing pill burden from 6 to 3 capsules/day) and capture 30-40% of the H. pylori segment across the P-CAB class. Second-generation P-CABs (fexuprazan, keverprazan): Fexuprazan (Daewoong Pharmaceutical, Korea) completed US Phase 3 trials for GERD in 2025, with FDA submission expected Q4 2026. Keverprazan (Livzon Pharmaceutical, China) is in Phase 3 for GERD and H. pylori (expected NMPA filing 2027). These next-generation molecules aim for improved pharmacokinetics (faster onset, longer duration) and lower drug-drug interaction potential. 4. Policy & Regulatory Drivers (2025-2026) China NRDL 2025 inclusion (effective Jan 2026): Vonoprazan (Takeda) and tegoprazan (Yuhan/Chia Tai Tianqing) added as Category B drugs, with national price negotiations resulting in 58-65% price reductions (from pre-NRDL average of $2.80-3.20/tablet to $1.00-1.20/tablet for branded products). Generic vonoprazan VBP prices are 40-50% lower ($0.50-0.70/tablet). China VBP Round 12 (January 2026): Included vonoprazan fumarate 10mg and 20mg tablets. Winning bids: Shandong New Era Pharmaceutical ($0.48/tablet – 82% reduction vs. pre-NRDL branded price), Luoxin Pharmaceutical ($0.52/tablet). Volume commitment: 80% of hospital GI prescriptions shifted to VBP-winning generics within 6 months. US FDA P-CAB landscape: Vonoprazan (Phathom’s Voquezna) approved 2023; tegoprazan (Yuhan/Phathom) in Phase 3 (expected NDA 2027); fexuprazan (Daewoong) in Phase 3 (expected NDA 2027-2028). No generic P-CABs expected in US until 2030-2032. EMA approvals: Vonoprazan approved November 2024 (Phathom/Takeda). Tegoprazan (Yuhan) filed MAA Q4 2025, expected approval Q3 2026. Reimbursement negotiations underway in Germany, France, UK, Italy, Spain (expected completion Q3-Q4 2026). Japan NHI price revisions (April 2025, April 2026): Vonoprazan price reduced 15% (2025) and additional 8% (2026) following generic entry (Sawai Pharmaceutical, Nichiiko). Takeda’s Takecab market share declined from 95% (2023) to 55% (Q1 2026) post-generic. Competitive Landscape: Key Suppliers The Potassium-Competitive Acid Blockers market features originator companies (Japan, Korea), US/EU licensees, and Asian generic manufacturers: Tier Vendors Focus Area Originators (Branded) Takeda (Japan – vonoprazan), Yuhan (Korea – tegoprazan), CJ Healthcare (Korea – revaprazan) Branded P-CABs, home markets, international licensing US/EU Licensees Phathom Pharmaceuticals (vonoprazan – US/EU), Yuhan/Phathom (tegoprazan – US/EU, Phase 3) Branded P-CABs, Western markets China Licensees & Generic Leaders Chia Tai Tianqing (tegoprazan licensee), East China Pharmaceutical (tegoprazan licensee), Shandong New Era Pharmaceutical (vonoprazan generic), Luoxin Pharmaceutical (vonoprazan generic) China VBP-winning generics, NRDL-branded products Japan Generic Sawai Pharmaceutical, Nichiiko (vonoprazan generic) Japan generic market Other notable players: None identified beyond the listed vendors – a concentrated market with originators/licensees holding 60% of global value share (branded premium pricing) and Asian generics holding 35% (volume, low price). Rest of world accounts for 5%. Original Analyst Perspective (30-Year Industry Lens) Having tracked GI therapeutics, acid suppressants (from H2 antagonists to PPIs to P-CABs), and global market dynamics across five continents, I observe three under-discussed trends: The P-CAB Class Effect Expansion Beyond Vonoprazan: While vonoprazan dominates today (72% share), tegoprazan’s aggressive China expansion (NRDL inclusion, dual licensees Chia Tai Tianqing and East China Pharmaceutical) and next-generation molecules (fexuprazan, keverprazan) will fragment the class by 2030. By 2031, vonoprazan share is projected to decline to 55-60%, tegoprazan to reach 25-30%, and next-generation molecules to capture 10-15%. Investors should monitor Phase 3 readouts for fexuprazan (US, expected Q4 2026) and keverprazan (China, expected 2027). China VBP vs. US/EU Specialty Divergence: China (VBP market, 55% of global P-CAB volume by 2026) prioritizes lowest cost generics ($0.50-0.70/tablet) for hospital and primary care. Branded vonoprazan (Takeda) and tegoprazan (Chia Tai Tianqing, East China Pharmaceutical) retain niche in premium private hospitals and retail pharmacies willing to pay 2-3x for “original quality.” US/EU (specialty market, 35% of global value but only 15% of volume) prioritizes branded P-CABs ($2.00-2.20/tablet for vonoprazan) with patient assistance programs and physician education (P-CAB superiority over PPIs). Generic entry not expected until 2030-2032, providing 6-8 years of branded exclusivity. The H. pylori Eradication Growth Engine Across the Class: P-CABs’ superior efficacy in H. pylori eradication (92-95% success rate vs. 75-85% for PPI-based triple therapy) is driving adoption across all three molecules in East Asia (high H. pylori prevalence – 50-70% of adults). In China alone, H. pylori eradication represents 55-60% of P-CAB prescriptions (vs. 30-35% for GERD, 5-10% for peptic ulcers). As antimicrobial resistance (clarithromycin, levofloxacin) increases globally, P-CABs’ consistent acid suppression becomes critical for first-line eradication success – a key growth driver through 2030. However, vonoprazan and tegoprazan are not interchangeable for H. pylori; each requires molecule-specific eradication studies (vonoprazan has the strongest evidence base to date). Strategic Recommendations for Decision Makers For R&D & Portfolio Directors: Prioritize fixed-dose combinations (FDC) with amoxicillin for H. pylori eradication across the P-CAB class – pending approvals (China Q4 2026, US/EU 2027-2028) could capture 30-40% of the eradication segment, offering 15-20% price premium over separate tablets. For next-generation P-CABs (fexuprazan, keverprazan), differentiate on pharmacokinetics (faster onset, longer duration) and drug-drug interaction potential (lower CYP inhibition) to justify premium pricing in crowded class. For Marketing & Commercial Executives: In VBP markets (China), accept lower margins (80% hospital volume at $0.50-0.70/tablet) but leverage remaining 20% retail/e-commerce channel for premium-priced differentiated products (e.g., “original quality” branded P-CABs, patient education packaging, digital adherence tools). In specialty markets (US, EU, Japan), focus on class superiority messaging (rapid onset, sustained 24h control, no CYP2C19 variability, superior H. pylori eradication) over PPIs, rather than intra-class differentiation (vonoprazan vs. tegoprazan differences are subtle for most prescribers). Target gastroenterologists (specialist prescribers) first, then primary care. For Investors: Monitor gross margins: Branded P-CABs (Takeda Japan, Phathom US/EU, Yuhan Korea) achieve 75-85% margins. Chinese VBP generics operate at 15-20% margins but achieve volume-based profitability (scale of 100M+ tablets annually). Watch for Phathom Pharmaceuticals’ US market penetration (Q1 2026 data) for vonoprazan (Voquezna) – if the class captures >10% of US GERD prescriptions (vs. 3% in Q4 2025), P-CAB adoption could re-rate significantly. Conversely, slow adoption (payer restrictions, PPI inertia) would pressure class growth. Monitor China VBP Round 13 (expected Q3 2026) – tegoprazan may be included, further compressing prices but accelerating volume uptake for Yuhan’s licensees (Chia Tai Tianqing, East China Pharmaceutical). Conclusion & Next Steps The Potassium-Competitive Acid Blockers (P-CABs) market is at an inflection point: NRDL inclusion and VBP generic entry in China are accelerating volume adoption (estimated 40-50% CAGR through 2028 for the class), while US/EU specialty markets sustain premium pricing through 2030-2032 for vonoprazan and 2030-2032 for tegoprazan (pending approval). QYResearch’s full report provides 150+ data tables, vendor market shares by molecule (vonoprazan, tegoprazan, revaprazan), 5-year regional forecasts (North America, Europe, Asia-Pacific, RoW), and China VBP impact modeling through 2030. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp